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sponse is higher in these patients. Treatment effect sizes are
larger among patients who do not flare.
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Purpose: Few clinical trials have been performed in HOA. De-
spite the recent presentation of the European Ligue Against
Rheumatism recommendations, few is known with respect to the
way doctors treat symptomatic HOA patients.
Aim of this study: To describe the therapeutic uses of French
doctors in HOA according to the level of symptoms.
Methods: Prospective cross-sectional pharmacoepidemiologic
survey. A sample of 100 French rheumatologists (Rh) and 100
general practitioners (GPs) had to describe 2 HOA patients
presenting consecutively: either with a flare of symptoms, i.e.
pain score ≥ 50 mm on a VAS and functional index for hand OA
score (FIHOA [2]) ≥ 5, and or with quiescent symptoms (pain <
50 mm and FIHOA < 5). Patients were both genders, age ≥ 45
years, fulfilling the ACR criteria [1], and were initially separated
according to the level of symptoms. Data collected: Doctors
characteristics, patients demographic data and HOA description,
and treatments received. A pharmaco-economic evaluation was
also performed. Statistics: descriptive: numbers (%) and mean
(SD).
Results: 169 doctors (aged 50 years, 69% men) described 316
patients of which 178 (56%) were in the "flare" and 44% in the
non-flare group, 83% women (95% menopaused), mean age 66
years (10), mean BMI 25 (4), with a familial history of HOA in
60%. VAS Pain score rated 66 (9) mm in the flare group and
30 (11) mm in the non-flare group, and FIHOA averaged 12 (4)
and 4 (1) respectively. Treatments received: 88% in the flare
group vs 76% received level 1 or 2 analgesics (p = 0.004), 69%
vs 30% received an NSAID (p < 0.001) of whom 66 and 50%
were prescribed a gastroprotective drug respectively. 90% of the
patients in the flare group were prescribed a symptomatic slow-
acting drug in OA (SySADOA) vs 80% (p = 0.01). No difference
was observed between the groups regarding the duration of
treatments with the exception of level 1 analgesics (46 days
in the "non-flare" group vs 27; p<0.001). Topical NSAIDs were
used in 60% of patients in both groups. Steroids intra-articular
(IA) injections were performed in 16% of patients in the "flare"
group vs 4% (p < 0.001). Surprinsingly non pharmacological
therapies were more often used in "flare" patients: 38% vs 27%
(p = 0.03), and comprised physical therapy (10%), splints (22%)
and Spa therapy (6%). GPs prescribed more analgesics (93% vs
73%), more NSAIDs (62% vs 43%) and more physical therapy
(19% vs 3) than Rh. Conversely, Rh prescribed more splints
(30% vs 13), and more IA steroids (16% vs 5). Mean costs of
treatments were similar in both groups of patients (278 Euros,
patient’s perspective). Drugs accounted for 189 Euros in the
"flare" group vs 206.
Conclusions: We observed some differences between Rh and
GPs in their management of hand OA symptoms: more splints, IA
steroids injections and SySADOA prescription by RH, while GPs
use more analgesics/NSAIDs and surprisingly more physical
therapy. Further studies in this field are required to confirm our
results.
Funding: This study was financially supported by Expanscience
Laboratories (Courbevoie, France)
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Purpose: To determine the benefit and risk of NSAID-based pro-
phylaxis for ectopic bone formation amongst patients undergoing
total hip replacement (or revision) surgery.
Methods: A double-blind randomised placebo-controlled clini-
cal trial, stratified by treatment site and surgery (primary or
revision), was conducted in 20 orthopaedic surgery centres in
Australia and New Zealand. 902 patients undergoing elective
primary or revision total hip replacement surgery were randomly
allocated to 14 days treatment with ibuprofen (1200mg daily)
or matching placebo commenced within 24 hours of surgery.
Patients were only excluded if there was, in the opinion of the
responsible physician, a definite indication or contra-indication
for treatment with an NSAID during the 14 day study treatment
period. Outcomes were assessed 6 to 12 months after sugery
and included changes in self-reported hip pain and physical func-
tion (WOMAC), physical performance measures and radiographic
evidence of ectopic bone formation.
Results: There was only a 6% loss to follow-up for self-report
measures and a 12% loss to follow-up for radiographs. Six to
twelve months after surgery, there were no significant differences
between the ibuprofen and placebo groups for improvements in
hip pain (mean difference, 95% confidence interval: -0.1, -0.4
to 0.2, p = 0.6) or physical function (-0.1, -0.4 to 0.2, p = 0.5),
despite a much reduced risk of ectopic bone formation (relative
risk 0.69, 95% confidence interval 0.56 to 0.83) associated with
ibuprofen. There was a significantly increased risk of major
bleeding complications during the admission period (2.09, 1.00
to 4.39).
Conclusions: These data, from the largest-ever trial of prophy-
laxis against ectopic bone formation, do not support the use of
routine NSAIDs-based prophylaxis for patients undergoing total
hip replacement surgery.
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Purpose: Over 30,000 revision total knee replacements are per-
formed annually in the US, and the number is rising steadily.
Hospital and surgeon procedure volume are associated with
perioperative mortality and complications as well as patient re-
ported functional outcomes two years following primary TKR.
The objective of this study is to determine if hospital and sur-
geon volume of TKR as associated with pain, functional status,
range of motion and satisfaction two years following revision
TKR.
Methods: We used Medicare claims to identify all patients in
four states (IL, OH, NC, TN) who had revision TKR in 2000.
We contacted these patients by mail in 2002 and invited them
to participate in a survey to assess their outcomes of revision
TKR surgery. The survey included the pain and function sub-
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scales of the Western Ontario and McMaster Osteoarthritis Index
(WOMAC, scored 0-100, 100=best). We measured satisfaction
with a single item on overall satisfaction with surgery and range
of motion with single items on whether the patient could bend
the knee 90 degrees and straighten the knee completely. We as-
sessed the association between volume and outcome separately
for hospital and surgeon volume and also with a dichotomous
indicator for whether the patients was either operated upon on
in a lower volume center (≤100 cases per year) OR by a low
volume surgeon (≤12 cases per year). We refer to these as
Low Volume patients. (Several different ways of characterizing
volume yielded similar results.) Multivariate analyses used Proc
Genmod in SAS to account for clustering within surgeon practice
and to adjust for age, sex and income status.
Results: Of 741 respondents, 36% were operated upon in hos-
pitals with volume ≤ 100 cases per year and 12% were operated
upon by surgeons with volume ≤ 12 cases per year. 40% were
either operated upon in a low volume hospital or a low volume
center. These Low Volume patients were more likely than those
who were not low volume patients to have a WOMAC pain score
less than 50 (14% vs. 8%, p=0.01), to be dissatisfied with the
results of surgery (16% vs. 12%, p=0.07) and to have a WOMAC
function score < 50 (12% vs. 9%, p=0.11). We did not observe
an association between volume and range of motion. In logistic
regression analyses, Low Volume was a risk factor for a poor
pain outcome (OR=1.7, 95% CI 1.1, 2.8) for dissatisfaction (OR
1.5, 95% CI 1.0, 2.3) and for a poor functional outcome (OR 1.4,
95% CI 0.9, 2.3).
Conclusions: Patients operated upon in low volume centers
or by low volume surgeons are at greater risk of poor pain
and functional outcomes and dissatisfaction two years following
surgery. Volume appears to influence pain outcomes more than
outcomes. These data should be incorporated into conversa-
tions between physicians and patients about choice of hospital
and surgery for revision TKR and into policy discussions about
regionalization of TKR to large volume centers.
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Purpose: Total knee replacement (TKR) is a frequently used
procedure to relieve pain and improve quality of life in patients
with end stage knee OA. Centers performing low volumes of
TKR have worse outcomes than higher volume centers. Re-
gionalization policies that shift patients to higher volume centers
are being considered as a means of improving TKR outcomes.
The cost-effectiveness of having TKR in high volume centers,
as compared with low volume centers has not been established.
We sought to utilize recent data on volume-outcome relationship
in TKR to examine the cost-effectiveness of performing TKR in
high volume centers comparing to low volume centers.
Methods: We built a decision tree to estimate the incremental
cost per quality-adjusted year of life gained for two TKR strate-
gies over a two-year period following TKR: (1) having TKR in high
volume center (>200 TKR annually in Medicare population); and
(2) having TKR in a low volume center (<26 TKR annually).
Population characteristics, rates of complications and mortality
as well as quality of life after TKR stratified by hospital volume
were derived from Medicare claims data. Cost data were derived
from published literature. To further examine the sensitivity of
our results to variation in imperfect model parameters, we per-
formed a probabilistic sensitivity analysis, drawing values from
distributions for difference in costs between high and low volume
centers and the magnitude of volume-outcomes relationship.
Results: Having TKR in a low volume center was a dominated
(higher costs with lower life expectancy) strategy as long as
the cost of TKR in a low volume center was at least as high
as cost of TKR in high volume center. Even when the cost of
TKR in low volume center was 20% lower than the cost in a
high volume center, TKR in high volume center exhibited a cost-
effectiveness ratio of $53,000/QALY compared to the low volume
center. If decision makers are willing to pay $20,000 for each
QALY gained, delivery of TKR in high volume center will be more
cost-effective than in low volume center greater than 90% of the
time.
Conclusions: While a substantial number of TKRs are per-
formed in low volume centers, delivery of TKR in high volume
centers is not only more effective but also cost-effective. Debate
surrounding regionalization polices for improving the quality of
total joint replacement should include data on cost-effectiveness
in addition to the volume-outcome relationship
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Purpose: To evaluate whether and to what degree baseline
function and pain, as well as number of co-morbid conditions
prior to THR affect early outcome at 3 months.
Methods: The Swiss Hip study is an ongoing prospective 5-
center- study. Consecutive patients undergoing THR due to pri-
mary hip osteoarthritis are evaluated before and at regular in-
tervals after surgery. Early outcomes at 3 months are presented
among 504 individuals 50 years and older (mean age: 72.8
yrs, SD ± 9.7 and 48% were male). Physical function and pain
were measured using the function and the pain subscale of the
Western Ontario and McMaster Universities Osteoarthritis index
(WOMAC, computer touch screen version 3.1; QUALITOUCH,
transformed 0-100 scale). A total of 14 self-reported comorbid
conditions (CCs) were assessed using a validated Comorbidity
Index with an additional question on back pain. We compared
adjusted average function and pain at 3 month follow-up between
quartiles of baseline function and pain prior to surgery as well as
categories of CCs (<2, 2, 3 or more). All analyses controlled for
gender, age, body mass index, and center.
Results: Compared to individuals in the top quartile of function
before surgery (WOMAC function > 56), those in the bottom
quartile (WOMAC function ≤32) achieved 23% less function at 3
month follow-up (trend test: p < 0.0001). Similarly, compared to
individuals in the bottom quartile of pain before surgery (WOMAC
pain ≤ 40), those in the top quartile (WOMAC pain > 65) had
55% more pain at 3 month follow-up (trend test: p < 0.0001).
Furthermore, compared to individuals with less than 2 CCs,
mean adjusted function at 3 month follow-up was 5% lower
(trend test: p = 0.08), and adjusted pain was 25% higher (trend
test: p = 0.04) in individuals with 3 or more CCs. 179 individuals
reporting back pain prior to surgery gained 6% less function (p =
0.007) and had 43% more pain (p = 0.002) at 3 month follow-up
independent of other co-morbid conditions.
Conclusions: Function and pain at 3 months after THR vary
